Tivic Health Systems Appoints Lisa Wolf as CFO, Blake Gurfein Transitions to Consultant Role

Tivic Health Systems has appointed Lisa Wolf as permanent CFO, effective July 7, 2025. Wolf's new role includes a base salary and potential bonuses, with her employment being 'at will.' Concurrently, Blake Gurfein transitioned from Chief Scientific Officer to a consultant role on July 4, 2025, to support the company's vagus nerve stimulation program. Several proposals were also approved during the Annual Meeting on June 30, 2025.

Tivic Health Systems Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, has announced significant changes in its leadership and strategic direction following its annual meeting on June 30, 2025. The company appointed Lisa Wolf as the permanent Chief Financial Officer (CFO) and Blake Gurfein as a consultant to support its vagus nerve stimulation (VNS) program.

Lisa Wolf, who has been serving as the interim CFO for the past nine months, assumed the permanent role effective July 7, 2025. Her appointment includes a base salary and potential bonuses, with her employment being 'at will.' Wolf's experience in senior leadership roles on Tivic's finance team over the past three years has been instrumental in supporting the company's financial architecture during its expansion.

Blake Gurfein, who served as the Chief Scientific Officer for eight years, transitioned to a consultant role on July 4, 2025. Gurfein will continue to support Tivic's VNS program, including product and intellectual property development, in his new capacity. His leadership has been pivotal in developing and commercializing ClearUP, the company's first FDA-approved product.

During the annual meeting, shareholders approved key proposals necessary for the company's strategic transformation. These proposals included the issuance of equity as a form of payment for Tivic's worldwide exclusive license agreement for Entolimod and Entolasta, which are being developed for uses in acute radiation syndrome, neutropenia, and other oncology and hematology indications. Additionally, shareholders approved the company's issuance of equity in accordance with previously announced financing arrangements, both of which were required under Nasdaq listing rules [1][2].

Tivic Health CEO Jennifer Ernst stated, "We have established a strong foundation for Tivic’s expansion into biopharmaceutical markets -- starting with commercialization of Entolimod for two large-market indications. We have already received strong customer interest in Entolimod’s national defense applications as a potential treatment for acute radiation syndrome. We have also secured exclusive rights for its use in the treatment of neutropenia, a market currently estimated to reach nearly $21 billion worldwide by 2032."

The company's strategic transformation aims to leverage its portfolio of biochemical and bioelectric therapies to treat underserved medical conditions. Tivic Health's lead biopharma product candidate, the TLR5 agonist Entolimod™, has been granted Fast Track and Orphan Drug designation by the FDA.

References:
[1] https://www.investing.com/news/stock-market-news/tivic-health-stock-rises-after-shareholders-approve-strategic-proposals-93CH-4126570
[2] https://www.businesswire.com/news/home/20250708263695/en/Tivic-Shareholders-Approve-Key-Proposals-in-Support-of-Strategic-Transformation-Lisa-Wolf-Appointed-Permanent-CFO